RecruitingPhase 2NCT06448754

Volrustomig Priming Regimens Exploratory Phase II Platform Study

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)

Sponsor

AstraZeneca

Enrollment

180 participants

Start Date

Aug 27, 2024

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 130 Years

Plain Language Summary

Simplified for easier understanding

This Phase II study explores different "priming" regimens to give alongside volrustomig, a dual immune checkpoint inhibitor, in advanced non-small cell lung cancer. The goal is to find which combination approach best activates the immune system against the tumor. **You may be eligible if...** - You have histologically confirmed advanced non-small cell lung cancer (NSCLC) - Your tumor does not have sensitizing EGFR mutations - You have good overall function (ECOG 0 or 1) and adequate organ function - Your body weight is above 35 kg - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have EGFR mutations in your tumor - Your overall health is too poor to tolerate treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVolrustomig

Participants will receive volrustomig via intravenous (IV) infusion.

DRUGCarboplatin

Participants will receive carboplatin via IV infusion.

DRUGPemetrexed

Participants will receive pemetrexed via IV infusion.

DRUGRamucirumab

Participants will receive ramucirumab via IV infusion.

DRUGPaclitaxel

Participants will receive paclitaxel via IV infusion.

Locations(77)

Research Site

Los Angeles, California, United States

Research Site

Grand Junction, Colorado, United States

Research Site

Wheat Ridge, Colorado, United States

Research Site

Baltimore, Maryland, United States

Research Site

Detroit, Michigan, United States

Research Site

Chapel Hill, North Carolina, United States

Research Site

Tacoma, Washington, United States

Research Site

Montreal, Quebec, Canada

Research Site

Beijing, China

Research Site

Hangzhou, China

Research Site

Jinan, China

Research Site

Yantai, China

Research Site

Zhengzhou, China

Research Site

Bois-Guillaume, France

Research Site

Caen, France

Research Site

Créteil, France

Research Site

Dijon, France

Research Site

Montpellier, France

Research Site

Batumi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Athens, Greece

Research Site

Athens, Greece

Research Site

Elaiones, Greece

Research Site

Piraeus, Greece

Research Site

Thessaloniki, Greece

Research Site

Genoa, Italy

Research Site

Meldola, Italy

Research Site

Milan, Italy

Research Site

Naples, Italy

Research Site

Orbassano, Italy

Research Site

Perugia, Italy

Research Site

Rozzano, Italy

Research Site

Udine, Italy

Research Site

Verona, Italy

Research Site

Kuala Lumpur, Malaysia

Research Site

Kuching, Malaysia

Research Site

Perai, Malaysia

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Lisbon, Portugal

Research Site

Porto, Portugal

Research Site

Porto, Portugal

Research Site

Cluj-Napoca, Romania

Research Site

Craiova, Romania

Research Site

Floreşti, Romania

Research Site

Belgrade, Serbia

Research Site

Belgrade, Serbia

Research Site

Kamenitz, Serbia

Research Site

Kragujevac, Serbia

Research Site

Seongnam, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Suwon, South Korea

Research Site

A Coruña, Spain

Research Site

Alcorcón, Spain

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Málaga, Spain

Research Site

Pamplona, Spain

Research Site

Santander, Spain

Research Site

Santiago de Compostela, Spain

Research Site

Valencia, Spain

Research Site

Valencia, Spain

Research Site

Basel, Switzerland

Research Site

Geneva, Switzerland

Research Site

Lausanne, Switzerland

Research Site

Winterthur, Switzerland

Research Site

Zurich, Switzerland

Research Site

Changhua, Taiwan

Research Site

New Taipei City, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06448754

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738301 locations

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT0606804925 locations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386299 locations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT0614703715 locations